{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=6&q=DLBCL", "query": { "q": "DLBCL", "condition": "Lymphoma", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 477, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=7&q=DLBCL&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=5&q=DLBCL&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T03:14:56.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04182204", "title": "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2020-02-07", "completion_date": "2024-11-29", "has_results": true, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 7, "location_summary": "Jacksonville, Florida • Pembroke Pines, Florida • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04182204" }, { "nct_id": "NCT03934814", "title": "Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "TJ011133", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2019-04-16", "completion_date": "2023-01-10", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934814" }, { "nct_id": "NCT03287817", "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "AUTO3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-09-05", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Miami, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287817" }, { "nct_id": "NCT02203526", "title": "Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Isavuconazole", "type": "DRUG" }, { "name": "TEDDI", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "TEDD", "type": "DRUG" }, { "name": "Ibrutinib (Arms 2, 3 and 4)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ibrutinib (Arm 1 - Closed with Amendment G)", "type": "DRUG" }, { "name": "Ibrutinib (Arm 4)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2014-08-14", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203526" }, { "nct_id": "NCT00931918", "title": "Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2009-10", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 70, "location_summary": "Beverly Hills, California • Fountain Valley, California • Fullerton, California + 58 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931918" }, { "nct_id": "NCT02503423", "title": "Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "ASTX660", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2015-07-14", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02503423" }, { "nct_id": "NCT00918463", "title": "A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2009-06", "completion_date": "2011-05-23", "has_results": true, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918463" }, { "nct_id": "NCT06120504", "title": "A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Cutaneous", "Hodgkin Disease", "Lymphoma, T-Cell, Peripheral", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "PF-08046045", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2024-02-29", "completion_date": "2025-12-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 15, "location_summary": "Palo Alto, California • Coral Gables, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120504" }, { "nct_id": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 20, "start_date": "2026-12-08", "completion_date": "2031-10-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07714421" }, { "nct_id": "NCT01410630", "title": "FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Lymphoma, Non-Hodgkin", "Large B Cell Diffuse Lymphoma" ], "interventions": [ { "name": "FLT-PET/CT", "type": "DIAGNOSTIC_TEST" }, { "name": "FDG-PET/CT", "type": "DIAGNOSTIC_TEST" }, { "name": "FLT", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 66, "start_date": "2017-09-07", "completion_date": "2019-10-04", "has_results": false, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-11T03:14:56.220Z", "location_count": 3, "location_summary": "Los Angeles, California • Omaha, Nebraska • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410630" } ] }